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Proof of the Germ theory of disease and acceptance of Koch’s postulates in the late 1890’s launched the fields of
microbial pathogenesis and infectious diseases and provided the conceptual framework that has guided thought
and research in these fields. A central tenet that emerged from studies with microbes that fulfilled Koch’s postulates
was that microbes that caused disease had characteristics that allowed them to do so, with the corollary that
microbes that did not cause disease lacked disease-causing determinants. This observation, which held true for
many diseases that were known to cause disease in the late 19th century, such as toxin-producing and encapsulated
bacteria, led to the view that the ability to cause disease rested with microbes and reflected the activity of specific
determinants, or virulence factors. With the dawn of the 20th century, efforts to neutralize virulence factors were
under development and ultimately translated into anti-microbial therapy in the form of antibodies targeted to toxins
and polysaccharide capsules. However, the 20th century progressed, antibiotics were identified and developed as
therapy for infectious diseases while other medical advances, such as specialized surgeries, intensive care units,
intravenous catheters, and cytotoxic chemotherapy became commonplace in resourced nations. An unintended
consequence of many of these advances was that they resulted in immune impairment. Similarly, HIV/AIDS, which
emerged in the late 1970’s also produced profound immune impairment. Unexpectedly, the prevailing view that
microbes were the sole perpetrators of virulence was untenable. Microbes that were rarely if ever associated with
disease emerged as major causes of disease in people with impaired immunity. This phenomenon revealed that
available explanations for microbial infectiveness and virulence were flawed. In this review, we discuss the question
‘what is infectiveness’ based on the tenets of the Damage-response framework.Introduction
The Germ theory was proven in the late 1890’s. For
almost a century thereafter a question such as ‘what is
infectiveness’ would have been considered naive. This is
because after proof of Koch’s postulates and acceptance
of the Germ theory, infectiveness was assumed to be a
property of microbes that caused disease and microbes
were considered to be solely responsible for disease
pathogenesis with those that caused disease being funda-
mentally different than those that did not. These views
gave rise to the concept that the ability to cause disease
was a trait that stemmed from a particular microbial
component, such as a virulence factor. This concept fit* Correspondence: l.pirofski@einstein.yu.edu
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article, unless otherwise stated.very well with microbial capsules, which could be identi-
fied with immune sera through capsular reactions, and
toxins, which could be identified by toxicity in animals.
An absence of these factors was considered to be suffi-
cient for rendering a microbe non-pathogenic. The iden-
tification of virulence factors provided a rational basis
for the development of pharmacological, genetic, and
immunological ways to prevent their production and
inhibit their modes of action. The latter resulted in the
development of antibody-based therapies that mediated
toxin neutralization and overcame the deleterious effects
of capsular polysaccharides [1]. Antibody therapies that
targeted virulence factors were the first rationally devel-
oped antimicrobial agents. Microbes with capsules and
toxins were highly prevalent at the time the Germ
Theory was developed and there were experimental
platforms and animal models to probe their ability to
cause disease. Although other microbes were also known
to be able to cause disease, such as viruses, experimentald Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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such, there was no reason to question whether a microbe
that was capable of causing disease would do so, or
whether a microbe might cause disease in one host, but
not in another. However, times change; and increasingly
since the 1980s, a century after the Germ theory was




Infectiveness is best defined as the property of being
infectious. Thus, infectiveness is part of infection. Infec-
tion is the event that occurs when a host acquires a
microbe, or the microbe ‘infects’ the host [2]. Although
the terms infection and disease are often erroneously
used as synonyms, they are not synonyms as evidenced
by the example that HIV infection is not the same as
AIDS. For any given microbe and host at a given time in
a given environmental context, infection results in an
outcome in the host that is defined by microbial factors,
host factors, and host-microbe interactions. For most
microbes, these outcomes are: elimination, commensal-
ism, colonization, disease, or latency. According to defi-
nitions put forth in the Damage-response framework,
the states of commensalism, colonization, disease, and
latency differ from one another by the amount of
damage in the host [3]. The Damage-response framework,
a theory of microbial pathogenesis, is discussed in detail in
the following articles [2-6].
There are some clear read-outs of host damage, such
as clinical signs and symptoms and laboratory and radio-
graphic abnormalities. When damage reaches a certain
threshold, there is clinical disease, though we note that
clinicians and researchers would each benefit from the
availability of more measures of host damage. Nonethe-
less, based on available tools, colonization, commensal-
ism, disease and latency are associated with a degree of
‘evidence’ of host-microbe interaction. For commensal-
ism, this evidence is presence of the microbiota. While
for other states, this evidence is damage or inflammation
in the host, which differs depending on the state. For
latency, evidence of damage can vary but what is import-
ant is that the amount of damage is not manifested
clinically. For Mycobacterium tuberculosis, the granu-
loma is a pauci-bacterial state that indicates the bacter-
ium is present as well as a signature of host damage.
This granuloma causes local damage in the lung but this
damage does affect normal homeostasis, and conse-
quently there is no disease. For herpesviruses, it is the
presence of virus in rare cells that is indicative of the
presence of virus in a host, whereas for hepatitis B and
C, a latent state can be manifested by measureable virus
without liver damage that is clinically manifest. In thelatter instance, some might refer to the latent state as
persistence. To the extent that latency and persistence
each mean that the microbe is present in the host in a
state that does not cause clinically manifest host damage,
the terms are interchangeable.
As noted above, the Damage-response framework
views the states of host-microbe interaction; commensal-
ism, colonization, disease and latency, as continuous and
different only in the extent of damage that occurs in the
host. Hence, infection with a single microbe can result
in more than one state in different hosts as well as in
different states in a single host at different times, and
sometimes simultaneously. For example, in a patient
with bacteremia caused by Staphylococcus aureus who is
colonized with this organism in the nares the same
organism is present in the states of disease and
colonization in the same individual. This highlights why,
as put forth in the Damage-response framework [2,5],
virulence cannot be a singular function of either microbe
or host. In designating host damage as the read-out of
host-microbe interaction, the Damage-response frame-
work differs from theories of microbial pathogenesis that
attribute virulence to either host or microbial factors.
Therefore, infectiveness is defined by the quantity and
quality of host damage that follows a host-microbe inter-
action. In this regard, infectiveness and virulence argu-
ably represent the same property.
The word ‘infectiveness ’is etymologically related to
the word infection. Given that infection is sometimes
meant to convey contagiousness, the relationship of
‘contagiousness’ to ‘infectiveness’ must also be consid-
ered. Although infection is often associated with trans-
missibility, or communicability, only some microbes are
transmitted from person. Modes of microbial transmis-
sion include person to person, vector to person, and
environment to person. Although transmission, or com-
municability, is sometimes related to virulence, transmis-
sion and virulence are not necessarily linked. For
example, Candida albicans is transmitted from mother
to child soon after birth, but with the exception of
occasional cases of neonatal candidiasis, acquisition of
Candida at this time rarely causes damage or disease in
immunologically intact individuals. Hence, transmission
of Candida is generally not associated with virulence.
On the other hand, viral agents, such as measles, are
transmitted from person to person and transmission is
generally associated with the development of disease in
non-immune people. Thus, transmission of measles is
associated with virulence, but only in a susceptible
(non-immunized) host. In the case of Cryptococcus neo-
formans, the microbe is acquired from the environment.
Infection is not always associated with disease and the
nature of disease depends on the immune status of the
host and the tissue that is infected. In the case of people
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lungs and the outcome is either elimination or a state of
latency. On the other hand, in people with acquired im-
mune impairment, most commonly due to HIV/AIDS or
solid organ transplantation, but occasionally in people
with what seems to be normal immunity, infection can
transition to disease. This can happen by progression of
an initial infection or when the fungus escapes the qui-
escent state of latency and disseminates from the lungs
to the bloodstream and brain. These examples show that
transmission is required for infection, and infection is
required for damage and disease, but damage and dis-
ease depend on the immune status of the host in
addition to microbial and environmental factors. Thus,
‘infectiveness’ is required for virulence, because infection
is a necessary pre-condition for virulence, whereby viru-
lence is the amount and degree of host damage stem-
ming from host-microbe interaction. Time is also an
important variable for virulence, because a microbe that
does not cause damage in a host at one time might do
so at another. For example, Candida can cause damage
and disease long after infection originally occurred in
someone who develops impaired immunity. On the
other hand, measles might cause damage and disease in
a non-immune person soon after infection. Thus, rela-
tionships between infectiveness and transmissibility and
virulence are a complex function of time and microbial,
host, and environmental factors.
For any given microbe, not all instances of infection
result in the same outcome. This is because the degree
and type of host damage is a function of characteristics
of the microbe and the host response. The host response
can vary from weak to strong, with weak and strong
serving as basic terms to denote responses that are asso-
ciated with a paucity of inflammation or an insufficient
inflammatory response (weak) and those that are associ-
ated with too much inflammation or an excessive in-
flammatory response (strong). For most host-microbe
interactions, neither weak nor strong responses are able
to completely minimize host damage. Thus, either a
weak or a strong host response can result in damage
that translates into disease. In general, weak responses
fail to restrict microbial growth and damage is primarily
due to microbial burden. On the other hand, strong
responses tend to produce damage due to excessive
inflammation. The outcome of host-microbe interaction
is also a crucial determinant of the response to anti-
microbial therapy. For example, a weak host response is
unlikely to be sufficient to induce microbial clearance,
making antimicrobial chemotherapy necessary to reduce
the microbial burden, with the caveat that drugs alone
cannot always eradicate a microbe. On the other hand,
although a strong host response (and/or effective anti-
microbial therapy) might induce microbial clearance, hostdamage can occur due to ongoing inflammation. These
scenarios each call for immune modulation. For example,
patients with disseminated Mycobacterium tuberculosis
infection can benefit from immunotherapy, such as ad-
junctive IFN-g therapy to enhance inflammatory re-
sponses, while individuals with tuberculous meningitis
can benefit from corticorsteroids to reduce inflammation.
The effect of host and microbial change on the outcome
of host-microbe interaction
Progress in medicine from the early 1970’s onward
brewed a perfect storm for infectious diseases and ques-
tions about microbial pathogenesis. This period witnessed
the advent of powerful immunosuppressive drugs that
transformed organ transplantation from a rare, high risk
procedure into a standard, albeit specialized, operation [7],
with the unintended consequence of inducing immune
impairment. Similarly, other medical advances such as
cytotoxic chemotherapy, radiation, and routine use of
intravenous catheters also induced impaired cellular and
mucosal immunity. This period also marked the onset of
the HIV/AIDS pandemic, a global catastrophe [8] that
rendered previously immunologically intact individuals
profoundly immunodeficient. Together, HIV/AIDS, med-
ical therapies, and interventions that caused immuno-
suppression led to the emergence of an unprecedented
number of people with de novo, acquired impaired im-
munity [4]. These individuals were highly susceptible to
the development of disease with certain microbes, some of
which rarely if ever caused disease previously in immuno-
competent people. These microbes included non-endemic
fungi, most notably Cryptococcus neoformans, Candida
albicans, and Pneumocystis spp. In addition, certain mi-
crobes exhibited an increased propensity to cause disease
in patients with impaired immunity, including bacteria
such as Mycobacterium tuberculosis, Streptococcus pneu-
moniae, Haemophilus influenzae Type B, Neisseria menin-
giditis, and bartonella; reactivated herpesviruses such as
Epstein Barr virus, cytomegalovirus, and the etiologic
agent of Kaposi’s sarcoma; and parasites such as Toxo-
plasma gondii. The emergence of diseases due to the
foregoing microbes in immunocompromised patients
led to intensive research that markedly advanced our
understanding of host defense and the immune response
to different microbes.
While the immune status of people changed, the
ability of microbes to cause damage and disease also
changed. This underscores the definition put forth in the
Damage-response framework that virulence is the
amount of damage that occurs in a susceptible host as a
result of host-microbe interaction and that it cannot be
defined independently of a host [2,5]. Beginning in the
1980’s, use, overuse, and abuse of broad-spectrum anti-
bacterial drugs (antibiotics) led to the emergence of
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resistant to all available antibiotics. Some antibiotic
resistance is intrinsic, and some, such as that of
Staphylococcus aureus and Neisseria gonorrhea to
penicillin, began much earlier than the 1980’s. How-
ever, the crisis in antimicrobial therapy [9] became a
catastrophe when it coincided with an expanding popu-
lation of patients with impaired immunity and led to an
inability to reliably treat infectious diseases in vulner-
able patients. This failure of therapy was twofold. On
one hand, there was a paucity of drugs to treat drug-
resistant microbes. On the other hand, patients with
impaired immunity were more susceptible to disease
with microbes that rarely if ever caused disease in im-
munocompetent people, underscoring the central im-
portance of the immune status of the host in microbial
virulence.
Along with the emergence of resistant microbes, mi-
crobial niches changed too. For example, an increase in
global travel led to the arrival of microbes with previ-
ously restricted borders in new venues, such as resistant
Streptococcus pneumoniae (pneumococcus), which spread
from Spain to the rest of the world [10,11]. Pneumococcus
and many other bacteria need to travel from person to
person, but microbes that do not require human hosts
were also on the move. West Nile virus, a mosquito borne
microbe (arbovirus), arrived in the northeastern United
States with a change in avian migration [12]. In addition,
climate change, particularly global warming and other
weather events such as El Nino, tornados, and other catas-
trophes, led to epidemics of cholera and other water borne
microbes [13]. Ecological changes, climate change, and
changes in sanitation and water handling promote vector
migration and vector borne zoonoses [14]. An increase in
fungal diseases in mammalian hosts has been hypothe-
sized to follow global warming [15]. Hence, environmental
forces have altered microbial niches and fostered microbial
proliferation.
The involvement of innate immunity in infectiveness
A major discovery that changed our understanding of the
relationship between immunity and infectiveness was the
discovery of pattern recognition receptors (PRRs) and the
subsequent unraveling of their role in host defense [16,17].
PRRs include toll like receptors (TLRs) and other, mainly
C-type lectin, receptors on host immune cells and tissues
that recognize microbial determinants. The discovery of
these moieties identified the initial interaction between a
microbe and immune cell or tissue as a critical determin-
ant of the success or failure of host defense, underscoring
the pivotal role of the host-microbe relationship in the
development of immunity. Our understanding of PRR-
microbial interaction was initially limited to a few exam-
ples, such as TLR2 binding to microbial cell wall glucans,lipoteichoic acid, and peptidoglycans; TLR4 binding to
lipopolysaccharide and HSP60, TLR5 binding to flagellin;
and TLR9 binding to CPGs. Subsequently, C-type lectin
PRRs, such as dectin-1, which bind fungal cell wall deter-
minants, retinoic acid inducible gene-like receptors (RLRs)
that bind viral RNAs, such as RIG-1, were identified as
were the signaling pathways that result in the production
of inflammatory cytokines and mediators, such as those
mediated by nucleotide-binding domain, leucine-rich
repeat- containing (NOD) proteins [18]. Together the
discovery of PRRs and their signaling pathways revealed
critical mechanisms by which host-microbe interaction
at the host cell interface leads to microbial clearance
and immunity. Evasion of PRR binding is a mechanism
by which some microbes can avoid or subvert host
defense. There is now abundant evidence that genetic
polymorphisms and defects in PRRs and their down-
stream signaling and cytokine production pathways
predispose certain patients to disease with certain mi-
crobes [19]. Thus, genetic defects and the infectious
diseases to which they predispose patients can serve as
sentinels that define the relationship between immunity
and infectiveness. Such defects include those that affect
the response to many microbes, via global pathways,
as well as those that affect the response to specific
microbes [20,21]. The complex role of genetics in
susceptibility to disease is highlighted by the way in
which mutations affect immune responses to Epstein
Barr virus infection [22].
Another recently recognized component of the innate
immune system that links immunity to infectiveness is
the IgM memory B cell repertoire [23]. Circulating and
marginal zone IgM memory B cells with the pheno-
type IgMhiIgDloCD27+ are now recognized as ‘first
responders’ in the host response to microbes. People
who lack these cells, which are depleted in patients
with HIV infection (see [24]), aging [25], and common
variable immunodeficiency [26] are more susceptible
to diseases caused by encapsulated microbes such as
Streptococcus pneumoniae [27] and Cryptococcus neo-
formans [24]. The origin of these cells and the extent
to which they are homologs of mouse B1-B cells re-
mains a matter of debate. Nonetheless, they have
been linked to serological memory for microbes for
over a decade [28]. IgM memory B cells are known
to be activated in a T-independent fashion in the
absence of antigen stimulation, including by CPGs via
TLR9, and to produce natural IgM that binds con-
served microbial determinants, such as cell wall carbo-
hydrates [23,29,30].
The involvement of infectiveness in acquired immunity
The ability of microbial determinants to induce immun-
ity and protection against infectious diseases has been
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ment of immune sera as the inaugural antimicrobial
agents, the power of induced immunity to defined
microbial determinants has been harnessed in vaccines.
In fact, resourced countries where infant/childhood vac-
cination is standard have enjoyed an unprecedented
sense of safety from childhood diseases due to vaccine-
mediated protection against measles, rubella, mumps,
varicella, polio, pertussis, Haemophilus influenzae Type
B, and pneumococcus. At the present time, even where
there is access to vaccines, vaccine refusal, serotype
replacement, and uncertainty about the duration of
protection pose roadblocks to complete prevention of
pertussis, mumps, measles, and pneumococcus. In
addition, currently there are no licensed vaccines for
malaria or other parasites, tuberculosis, dengue, fungi,
or drug resistant bacteria. Nonetheless, immunization
has markedly reduced rates of the aforementioned dis-
eases, eliminated smallpox globally, and provides hope
that other vaccine-preventable diseases can be elimi-
nated. The ability of immunization to prevent infectious
diseases provides incontrovertible evidence of the
essential role of host immunity in disease prevention.
Immune people rarely develop full-blown disease.
Vaccine-elicited protection is ‘ready-made’ as long as
the vaccine recipient has had enough time to develop
immunity. On the other hand, natural immunity can
take time to develop in a naïve host and is not always
sufficient to prevent disease. As for the effect of
acquired immunity on infectiveness, immunity prevents
disease, but might not prevent infectiveness. Some
vaccines do not prevent infection despite their ability to
prevent disease and some vaccines, measles, mumps,
rubella, and varicella are live agents.
Summary and conclusions
In this review, we have addressed the question ‘what is
infectiveness’ based on definitions of microbial patho-
genesis and virulence put forth in the Damage-
response framework. Our take home message is that
‘infectiveness’ , like virulence and the states in which
microbes are found in hosts, is an outcome of host-
microbe interaction that is a complex function of time
and microbial, host, and environmental factors inde-
pendently and in combination. However, the emer-
gence of new infectious diseases and occurrence of
epidemics challenge the ability of available theories
and paradigms to incorporate new information. Along
these lines, the seemingly infinite combinations of
host, microbe, and environment that can emerge in
any given host-microbe interaction begs another ques-
tion: how can new diseases and discoveries about hosts
and microbes be incorporated into current thinking?
Here is our answer: we think the following aspects ofthe Damage-response framework [4] provide a way to
address this challenge:
1. The only terms that are required to explain microbial
pathogenesis are ‘host’ and ‘microbe’ with the relevant
read-out of their interaction being damage in the
host; thus, designations of microbes as ‘pathogens’ ,
‘non-pathogens’ , ‘primary pathogens’ , ‘commensals’
are irrelevant.
a. Host damage can be a function of host or
microbial properties, or both.
2. Four states represent the outcome of host-microbe
interaction: commensalism, colonization, disease,
and latency.
a. The states are considered to be continuous and
to differ only in the degree of damage in the host
as a function of time.
3. Virulence is a microbial property that is defined by
the outcome of host-microbe interaction.
a. Virulence is an emergent property; it cannot be
predicted by host or microbial properties alone [31].
b. As an emergent property, virulence is influenced
by factors that affect microbial and host fitness,
including behavioral, environmental, political, as
well as host and microbial factors.
c. Thus, the Damage-response framework is able to
account for differences in the outcome of infection
between hosts (i.e. the same microbe can cause
damage and disease in one host, but not another)
and within hosts (i.e. the same microbe can cause
damage and disease at one time, but not after
immunization, prior infection, or under another set
of conditions).
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